form6vk
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of May 2007
Commission File Number 000-31062
Oncolytics Biotech Inc.
(Translation of registrant’s name into
English)
Suite 210, 1167 Kensington Crescent NW
Calgary, Alberta, Canada T2N 1X7
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports
under cover Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1): o
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a
Form 6-K if submitted solely to provide an attached annual report to security
holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): o
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a
Form 6-K if submitted to furnish a report or other document that the registrant
foreign private issuer must furnish and make public under the laws of the
jurisdiction in which the registrant is incorporated, domiciled or legally
organized (the registrant’s “home country”), or under the rules of the home
country exchange on which the registrant’s securities are traded, as long as
the report or other document is not a press release, is not required to be and
has not been distributed to the registrant’s security holders, and, if
discussing a material event, has already been the subject of a Form 6-K
submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this
Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of
1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g3-2(b): 82 -
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
| |
|
|
|
|
| |
|
Oncolytics
Biotech Inc.
(Registrant) |
| |
| |
|
|
|
|
| |
| Date: May 29, 2007 |
|
By: |
|
/s/ Doug Ball
Doug Ball
Chief Financial Officer |
 |
210, 1167 Kensington Crescent N.W.
Calgary, Alberta
Canada T2N 1X7 |
FOR IMMEDIATE RELEASE
Oncolytics Biotech Inc. Starts Patient Enrolment in
U.K. Combination REOLYSIN®/Paclitaxel and Carboplatin Trial
CALGARY, AB, — May 29, 2007 — Oncolytics Biotech Inc. (“Oncolytics”) (TSX:ONC, NASDAQ:ONCY) has
commenced patient enrolment in its U.K. clinical trial to evaluate the anti-tumour effects of
systemic administration of REOLYSIN® in combination with paclitaxel and carboplatin in
patients with advanced cancers including head and neck, melanoma, lung and ovarian. This trial is
one of three expected to begin in 2007 that will examine the role of REOLYSIN® in
combination with standard chemotherapeutics.
“This study is the first to examine the use of REOLYSIN® with drug combinations that are
used in first or second line therapy,” said Dr. Matt Coffey, Chief Scientific Officer for
Oncolytics. “Our collaborators have shown in preclinical studies that the activity of these agents
is dramatically enhanced by the addition of REOLYSIN® and we are pleased to be examining
this combination in patients.”
The principal investigators are Dr. Kevin Harrington of The Institute of Cancer Research and The
Royal Marsden NHS Foundation Trust, and Dr. Geoff Hall of St. James’s Hospital in Leeds, U.K.
The trial (REO 011) has two components. The first is an open-label, dose-escalating,
non-randomized study of REOLYSIN® given intravenously with paclitaxel and carboplatin
every three weeks. Standard dosages of paclitaxel and carboplatin will be delivered with
escalating dosages of REOLYSIN® intravenously. A maximum of three cohorts will be
enrolled in the REOLYSIN® dose escalation portion. The second component of the trial
will immediately follow and will include the enrolment of a further 12 patients at the maximum
dosage of REOLYSIN® in combination with a standard dosage of paclitaxel and carboplatin.
Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours
such as head and neck, melanoma, lung and ovarian cancers that are refractory (have not responded)
to standard therapy or for which no curative standard therapy exists. The primary objective of the
trial is to determine the Maximum Tolerated Dose (MTD), Dose-Limiting Toxicity (DLT), recommended
dose and dosing schedule and safety profile of REOLYSIN® when administered in
combination with paclitaxel and carboplatin. Secondary objectives include the evaluation of immune
response to the drug combination, the body’s response to the drug combination compared to
chemotherapy alone and any evidence of anti-tumour activity.
In the U.K. and the U.S., approximately 350,000 people are diagnosed annually with head & neck,
melanoma, lung and ovarian cancers.
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses
as potential cancer therapeutics. Oncolytics’ clinical program includes a variety of Phase I
and Phase II human trials using REOLYSIN®, its proprietary formulation of the human
reovirus, alone and in combination with radiation or chemotherapy. For further information about
Oncolytics, please visit www.oncolyticsbiotech.com
For more information about paclitaxel and carboplatin, please visit www.bms.com
This press release contains forward-looking statements, within the meaning of Section 21E of
the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the
Company’s expectations related to the U.K. combination REOLYSIN®/paclitaxel and
carboplatin clinical trial and the Company’s belief as to the potential of REOLYSIN® as
a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the
Company’s actual results to differ materially from those in the forward-looking statements. Such
risks and uncertainties include, among others, the availability of funds and resources to pursue
research and development projects, the efficacy of REOLYSIN® as a cancer treatment, the
tolerability of REOLYSIN® outside a controlled test, the success and timely completion
of clinical studies and trials, the Company’s ability to successfully commercialize
REOLYSIN®, uncertainties related to the research and development of pharmaceuticals and
uncertainties related to the regulatory process. Investors should consult the Company’s quarterly
and annual filings with the Canadian and U.S. securities commissions for additional information on
risks and uncertainties relating to the forward-looking statements. Investors are cautioned against
placing undue reliance on forward-looking statements. The Company does not undertake to update
these forward-looking statements.
FOR FURTHER INFORMATION PLEASE CONTACT:
| |
|
|
|
|
| Oncolytics Biotech Inc. |
|
The Equicom Group |
|
The Investor Relations Group |
| Cathy Ward |
|
Nick Hurst |
|
Erika Moran |
| 210, 1167 Kensington Cr NW |
|
325, 300
5th Ave. SW |
|
11 Stone Street, 3rd Floor |
| Calgary, Alberta T2N 1X7 |
|
Calgary, Alberta T2P 3C4 |
|
New York, NY 10004 |
| Tel: 403.670.7377 |
|
Tel: 403.538.4845 |
|
Tel: 212.825.3210 |
| Fax: 403.283.0858 |
|
Fax: 403.237-6916 |
|
Fax: 212.825.3229 |
| cathy.ward@oncolytics.ca |
|
nhurst@equicomgroup.com |
|
emoran@investorrelationsgroup.com |
| www.oncolyticsbiotech.com |
|
|
|
|
-30-